StockMarketWire.com - AstraZeneca announced 'positive' results from its trial which showed that its cardiovascular drug, when combinbed with Aspirin, reduced the relative risk of heart attack or stroke by 10% compared with aspirin alone.

The overall themis trial population included patients with coronary artery disease (CAD) and type-2 diabetes (T2D) with no prior heart attack or stroke.

The trial also showed a 15% relative risk reduction for Brilinta plus aspirin for the composite of CV death, heart attack, or stroke, compared with aspirin alone in patients who had previously undergone a percutaneous coronary intervention (PCI), a procedure to open a blocked or narrowed coronary artery, the company said.

'These positive results show that Brilinta reduced the risk of cardiovascular events in patients with coronary artery disease and type-2 diabetes, and we hope this will make a difference because their risk of heart attack or stroke is almost twice as high as it is among diabetes patients without cardiovascular disease,' said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D.

'Also, for the first time, these new data identified an easily-recognisable sub-group of stable patients who may benefit most from Brilinta - those with type-2 diabetes who have undergone PCI.'

Story provided by StockMarketWire.com